Anavex Life Sciences Corp (0HFR.L)

Name: Anavex Life Sciences Corp Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$0.0

Net Income

-$5.7M

Operating Margin

N/A

Free Cash Flow

-$39.0M

Debt / Assets

8.6%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Anavex Life Sciences Corp (0HFR.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	0	0	0	0
Cost of Revenue	0	0	0	0
Gross Profit	0	0	0	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	2,126,000	3,550,000	4,500,000	2,621,000
Operating Expenses	6,782,000	10,844,000	14,459,000	12,513,000
Operating Income	-6,782,000	-10,844,000	-14,459,000	-12,513,000
Interest Expense	0	0	0	0
Income Before Tax	-5,663,000	-9,827,000	-13,243,000	-11,196,000
Income Tax Expense	18,000	0	0	0
Net Income	-5,681,000	-9,827,000	-13,243,000	-11,196,000
Per Share
EPS	-0.06	-0.11	-0.16	-0.13
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Anavex Life Sciences Corp (0HFR.L).
Income Statement (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Revenue	0	0	0	0
Cost of Revenue	0	0	0	0
Gross Profit	0	0	0	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	13,816,000	11,039,000	12,039,000	13,070,068
Operating Expenses	51,408,000	52,877,000	55,756,000	50,985,815
Operating Income	-51,408,000	-52,877,000	-55,756,000	-50,985,820
Interest Expense	0	0	964,000	0
Income Before Tax	-46,377,000	-43,002,000	-47,498,000	-50,942,438
Income Tax Expense	0	0	7,000	-2,964,519
Net Income	-46,377,000	-43,002,000	-47,505,000	-47,977,919
Per Share
EPS	-0.54	-0.52	-0.60	-0.62
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Anavex Life Sciences Corp (0HFR.L).
Balance Sheet (Quarterly)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Cash and Cash Equivalents	102,577,000	132,187,000	151,024,000	149,157,861
Short Term Investments	0	0	0	0
Net Receivables	809,000	2,449,000	2,709,000	3,192,580
Inventory	0	0	0	0
Total Current Assets	103,815,000	135,567,000	154,386,000	152,704,603
Property Plant Equipment	0	0	0	0
Goodwill and Intangibles	0	0	0	0
Total Assets	103,815,000	135,567,000	154,386,000	152,704,603
Liabilities
Account Payables	4,249,000	9,627,000	4,322,000	3,824,777
Short Term Debt	0	0	0	0
Total Current Liabilities	8,946,000	15,304,000	12,534,000	10,213,561
Long Term Debt	0	0	0	0
Total Liabilities	8,946,000	15,304,000	12,534,000	10,213,561
Shareholders Equity
Retained Earnings	-382,448,000	-336,071,000	-293,069,000	-245,563,783
Total Shareholders Equity	94,869,000	120,263,000	141,852,000	142,491,042

Balance sheet annual history for Anavex Life Sciences Corp (0HFR.L).
Balance Sheet (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Cash and Cash Equivalents	102,577,000	132,187,000	151,024,000	149,157,861
Short Term Investments	0	0	0	0
Net Receivables	809,000	2,449,000	2,709,000	3,192,580
Inventory	0	0	0	0
Total Current Assets	103,815,000	135,567,000	154,386,000	152,704,603
Property Plant Equipment	0	0	0	0
Goodwill and Intangibles	0	0	0	0
Total Assets	103,815,000	135,567,000	154,386,000	152,704,603
Liabilities
Account Payables	4,249,000	9,627,000	4,322,000	3,824,777
Short Term Debt	0	0	0	0
Total Current Liabilities	8,946,000	15,304,000	12,534,000	10,213,561
Long Term Debt	0	0	0	0
Total Liabilities	8,946,000	15,304,000	12,534,000	10,213,561
Shareholders Equity
Retained Earnings	-382,448,000	-336,071,000	-293,069,000	-245,563,783
Total Shareholders Equity	94,869,000	120,263,000	141,852,000	142,491,042

Cash flow quarterly history for Anavex Life Sciences Corp (0HFR.L).
Cash Flow Statement (Quarterly)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Operating Activities
Net Income	-46,377,000	-43,002,000	-47,505,000	-47,977,919
Depreciation & Amortization	0	0	0	0
Stock Based Compensation	11,549,000	9,438,000	16,370,000	18,379
Change in Working Capital	-4,216,000	2,752,000	2,505,000	5,360,813
Operating Cash Flow	-39,044,000	-30,812,000	-27,785,000	-24,237,864
Investing Activities
Capital Expenditure	0	0	0	0
Investments	0	0	0	0
Investing Cash Flow	0	0	0	0
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	12,141,000	11,975,000	27,875,000	21,287,980
Dividends Paid	0	0	0	0
Financing Cash Flow	9,434,000	11,975,000	29,651,000	21,287,980
Summary
Free Cash Flow	-39,044,000	-30,812,000	-27,785,000	-24,237,864
Net Change in Cash	-29,610,000	-18,837,000	1,866,000	-2,949,884

Cash flow annual history for Anavex Life Sciences Corp (0HFR.L).
Cash Flow Statement (Annual)	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Operating Activities
Net Income	-46,377,000	-43,002,000	-47,505,000	-47,977,919
Depreciation & Amortization	0	0	0	0
Stock Based Compensation	11,549,000	9,438,000	16,370,000	18,379
Change in Working Capital	-4,216,000	2,752,000	2,505,000	5,360,813
Operating Cash Flow	-39,044,000	-30,812,000	-27,785,000	-24,237,864
Investing Activities
Capital Expenditure	0	0	0	0
Investments	0	0	0	0
Investing Cash Flow	0	0	0	0
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	12,141,000	11,975,000	27,875,000	21,287,980
Dividends Paid	0	0	0	0
Financing Cash Flow	9,434,000	11,975,000	29,651,000	21,287,980
Summary
Free Cash Flow	-39,044,000	-30,812,000	-27,785,000	-24,237,864
Net Change in Cash	-29,610,000	-18,837,000	1,866,000	-2,949,884